Epstein-Barr Virus Antibody to Viral Capsid Antigen, IgG and IgA
Also known as: EBV PAN 3
Use
This test is used to support the detection and monitoring of Epstein-Barr virus (EBV) serological status by detecting antibodies to the viral capsid antigen. It is particularly helpful in assessing nasopharyngeal carcinoma risk. While it is not suitable for diagnosing infectious mononucleosis, it can provide valuable information in specific clinical scenarios involving EBV.
Special Instructions
For proper result interpretation, label specimens as 'acute' or 'convalescent'. Parallel testing is preferred and convalescent specimens must be received within 30 days of the acute specimens.
Limitations
The test should not be used as a diagnostic tool for Epstein-Barr virus infectious mononucleosis. The performance characteristics of this test have not been cleared or approved by the US Food and Drug Administration. It is performed in a CLIA certified lab for clinical purposes but may have limitations in detection sensitivity and specificity based on the sample quality and patient's serological status.
New York Approved
Methodology
Immunoassay (ELISA)
Biomarkers
LOINC Codes
- 31369-2
- 7885-7
- 7885-7
- 31369-2
Result Turnaround Time
1-8 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
2 mL
Minimum Volume
0.5 mL
Container
Serum separator tube (SST)
Collection Instructions
Allow specimen to clot completely at room temperature. Separate from cells ASAP or within 2 hours of collection. Transfer serum to an ARUP standard transport tube.
Storage Instructions
Refrigerated transport required.
Causes for Rejection
Contaminated, heat-inactivated, icteric, or grossly hemolyzed specimens.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 48 hours |
| Refrigerated | 2 weeks |
| Frozen | 1 month (avoid repeated freeze/thaw cycles) |